NCT00911534

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 305 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).

Conditions

• Symptomatic Gastroesophageal Reflux Disease (sGERD)

Interventions

Type	Name	Description
DRUG	rabeprazole sodium	One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
DRUG	Placebo	One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-07-01
• Completion: 2009-10-01
• First posted: 2009-06-02
• Last updated: 2016-02-02
• Results posted: 2016-02-02

Locations

98 sites across 1 country: United States